Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Net Change in Cash?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1996 - 2021 (26 years)

Net Change in Cash is 
$1.1B (1Y +48.8% )

ALXN Stock Price & Net Change in Cash

Net Change in Cash for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Net Change in Cash

chevron_right 2021 $706.1M +58.8x *
( +17.0% / year avg)
chevron_left 1996 -$11.8M
vertical_align_top Peak $972.0M +2.72x *
vertical_align_bottom Bottom -$565.7M
arrow_drop_up # Up Years 9 9 of 26
years up.
arrow_drop_down # Down Years 17
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1996 , or -0.74x the rate relative to it's net change in cash over the same period.
  • If ALXN grows it's stock at the same rate as it's net change in cash (+17.0%/year) , it's stock price will grow +480% and hit $522.6 over the next 10 years.
  • ALXN's stock price has gone up 5 of the 9 years (+55%) it's net change in cash were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Net Change in Cash Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Net Change in Cash YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $706 463.1% $108.72 0.0%
    4/1/2020 $125 -87.1% $108.72 -4.6%
    4/1/2019 $972 43.1% $113.94 -7.5%
    4/1/2018 $679 -335.6% $123.15 12.1%
    4/1/2017 $-288 -49.0% $109.81 -12.8%
    4/1/2016 $-565 -237.6% $125.86 -26.9%
    4/1/2015 $411 -234.8% $172.19 1.7%
    4/1/2014 $-305 -6345.1% $169.29 57.1%
    4/1/2013 $4 -99.0% $107.76 0.5%
    4/1/2012 $467 104.8% $107.21 85.0%
    4/1/2011 $228 411.0% $57.95 105.2%
    4/1/2010 $44 8.5% $28.24 25.1%
    4/1/2009 $41 15.9% $22.56 0.1%
    4/1/2008 $35 -31.1% $22.54 49.1%
    4/1/2007 $51 -324.5% $15.12 61.0%
    4/1/2006 $-22 -248.0% $9.39 37.1%
    4/1/2005 $15 -75.0% $6.85 53.4%
    4/1/2004 $62 -768.0% $4.46 -4.9%
    4/1/2003 $-9 -90.7% $4.69 58.0%
    4/1/2002 $-99 -237.9% $2.97 -44.4%
    4/1/2001 $72 110.7% $5.33 -79.4%
    4/1/2000 $34 -311.0% $25.84 672.9%
    4/1/1999 $-16 757.9% $3.34 81.4%
    4/1/1998 $-1 -107.9% $1.84 -30.2%
    4/1/1997 $24 -305.1% $2.64 24.3%
    4/1/1996 $-11 - $2.12 -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • The net change in cash is the amount by which a company's cash balance increases or decreases in an accounting period.

    For more detailed definitions, please see Investopedia.